We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA OKs Genzyme’s Aubagio as Oral Treatment for Relapsing MS
FDA OKs Genzyme’s Aubagio as Oral Treatment for Relapsing MS
September 14, 2012
The FDA has approved Genzyme’s once-daily oral drug Aubagio for relapsing multiple sclerosis (MS), setting it up to compete with Novartis’ Gilenya.